| Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ... New England Journal of Medicine 379 (22), 2108-2121, 2018 | 3239 | 2018 |
| Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, ... New England Journal of Medicine 366 (6), 520-529, 2012 | 3205 | 2012 |
| Palbociclib and letrozole in advanced breast cancer RS Finn, M Martin, HS Rugo, S Jones, SA Im, K Gelmon, N Harbeck, ... New England journal of medicine 375 (20), 1925-1936, 2016 | 2206 | 2016 |
| Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy DG DeNardo, DJ Brennan, E Rexhepaj, B Ruffell, SL Shiao, SF Madden, ... Cancer discovery 1 (1), 54-67, 2011 | 1770 | 2011 |
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer KD Miller, LI Chap, FA Holmes, MA Cobleigh, PK Marcom, ... Journal of clinical oncology 23 (4), 792-799, 2005 | 1682 | 2005 |
| Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ... New England Journal of Medicine 380 (20), 1929-1940, 2019 | 1660 | 2019 |
| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation JK Litton, HS Rugo, J Ettl, SA Hurvitz, A Gonçalves, KH Lee, ... New England Journal of Medicine 379 (8), 753-763, 2018 | 1524 | 2018 |
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer KL Blackwell, HJ Burstein, AM Storniolo, H Rugo, G Sledge, M Koehler, ... Journal of clinical oncology 28 (7), 1124-1130, 2010 | 1117 | 2010 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1113 | 2018 |
| Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo … PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ... The Lancet 390 (10105), 1833-1842, 2017 | 1019 | 2017 |
| Breast cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual AE Giuliano, JL Connolly, SB Edge, EA Mittendorf, HS Rugo, LJ Solin, ... CA: a cancer journal for clinicians 67 (4), 290-303, 2017 | 908 | 2017 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 898 | 2020 |
| Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results … P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ... The Lancet Oncology 21 (1), 44-59, 2020 | 879 | 2020 |
| 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... The Breast 31, 244-259, 2017 | 825 | 2017 |
| Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells B Ruffell, D Chang-Strachan, V Chan, A Rosenbusch, CMT Ho, N Pryer, ... Cancer cell 26 (5), 623-637, 2014 | 821 | 2014 |
| ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F Andre, CH Barrios, ... The Breast 23 (5), 489-502, 2014 | 808 | 2014 |
| Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer J Baselga, V Semiglazov, P van Dam, A Manikhas, M Bellet, ... Journal of Clinical Oncology 27 (16), 2630-2637, 2009 | 794 | 2009 |
| Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer after prior HER2 … HA Burris, HS Rugo, SJ Vukelja, CL Vogel, RA Borson, S Limentani, ... Journal of Clinical Oncology 29 (4), 398-405, 2011 | 779 | 2011 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 746 | 2020 |
| Phase II trial of bicalutamide in patients with androgen receptor–positive, estrogen receptor–negative metastatic breast cancer A Gucalp, S Tolaney, SJ Isakoff, JN Ingle, MC Liu, LA Carey, K Blackwell, ... Clinical cancer research 19 (19), 5505-5512, 2013 | 746 | 2013 |
